Exemestane

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Exemestane (ncit:C1097)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (+)	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (+)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (+)	ER positive	Invasive Breast Carcinoma	Exemestane